* This work was supported by National Institutes of Health Grants
ES10442 and ES10806, the Backus Foundation, the Lookout Fund, and
by Mylan Pharmaceuticals. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Parkinson's Inst.,
1170 Morse Ave., Sunnyvale, CA 94089-1605. Tel.: 408-542-5602; Fax:
408-734-8522; E-mail: ddimonte@parkinsonsinstitute.org.
1 The abbreviations used are: PD, Parkinson's disease; Syn-1, anti-synuclein; PFA, paraformaldehyde; M.O.M., Mouse On Mouse Monoclonal; TH, tyrosine hydroxylase; ANOVA, analysis of variance; MPTP,
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
